TScan Therapeutics (NASDAQ:TCRX) Price Target Cut to $9.00 by Analysts at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX) had its target price reduced by Needham & Company LLC from $11.00 to $9.00 in a research report report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other equities analysts have also recently commented on the stock. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Price Performance

TScan Therapeutics stock opened at $1.92 on Wednesday. TScan Therapeutics has a 52 week low of $1.82 and a 52 week high of $9.69. The company’s 50 day moving average price is $2.45 and its two-hundred day moving average price is $4.06. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a market cap of $102.47 million, a P/E ratio of -1.81 and a beta of 0.87.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Checkpoint Capital L.P. purchased a new position in TScan Therapeutics in the 3rd quarter valued at approximately $4,110,000. abrdn plc grew its stake in TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares in the last quarter. State Street Corp grew its stake in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock valued at $851,000 after buying an additional 145,731 shares in the last quarter. Finally, Lynx1 Capital Management LP grew its stake in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock valued at $16,286,000 after buying an additional 132,747 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.